Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Molecular Targeted Therapy”

161 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 161 results

Testing effectiveness (Phase 2)UnknownNCT04586088
What this trial is testing

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Who this might be right for
Nasopharyngeal CarcinomaRecurrent Nasopharyngeal CarcinomaMetastatic Nasopharyngeal Carcinoma+3 more
Sun Yat-sen University 58
Testing effectiveness (Phase 2)UnknownNCT05981157
What this trial is testing

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Who this might be right for
Nasopharyngeal Carcinoma
Zhongshan People's Hospital, Guangdong, China 27
Testing effectiveness (Phase 2)Study completedNCT01728233
What this trial is testing

Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis

Who this might be right for
Penile NeoplasmsCarcinoma, Squamous Cell
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 32
Not applicableLooking for participantsNCT07498933
What this trial is testing

FAP-targeted PET/NIR in Lung Malignant Tumors

Who this might be right for
Non-Small Cell Lung CancerPET/CTNeoadjuvant Therapy
Peking University People's Hospital 200
Early research (Phase 1)Study completedNCT04670679
What this trial is testing

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Erasca, Inc. 90
Not applicableStudy completedNCT06881433
What this trial is testing

Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis

Who this might be right for
Hepatocellular Carcinoma (HCC)
Zhongda Hospital 1,649
Testing effectiveness (Phase 2)Looking for participantsNCT07049055
What this trial is testing

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Who this might be right for
Pancreatic Cancer, MetastaticPDAC - Pancreatic Ductal Adenocarcinoma
Engeneic Pty Limited 144
Not applicableNot Yet RecruitingNCT07775859
What this trial is testing

NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers

Who this might be right for
Gastrointestinal CancerGastric CancerGastroesophageal Junction Cancer+2 more
Peking University Cancer Hospital & Institute 200
Testing effectiveness (Phase 2)Ended earlyNCT02414750
What this trial is testing

Vemurafenib Plus Cobimetinib in Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Netherlands Working Group on Immunotherapy of Oncology 78
Not applicableLooking for participantsNCT04504604
What this trial is testing

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

Who this might be right for
Rare CancersCholangiocarcinomaCancer of Unknown Primary Site
TargetCancer Foundation 400
Not applicableActive Not RecruitingNCT03347318
What this trial is testing

Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease

Who this might be right for
Solid Tumors
Fondazione del Piemonte per l'Oncologia 2,500
Testing effectiveness (Phase 2)Study completedNCT02645149
What this trial is testing

Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma

Who this might be right for
Melanoma
Melanoma Institute Australia 216
Not applicableUnknownNCT02597179
What this trial is testing

Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer

Who this might be right for
Breast Cancer
Samsung Medical Center 350
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Not applicableStudy completedNCT02613962
What this trial is testing

Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling

Who this might be right for
Relapsed or Refractory Pediatric Tumor
Gustave Roussy, Cancer Campus, Grand Paris 791
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Early research (Phase 1)Study completedNCT01061411
What this trial is testing

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
Clear Cell Sarcoma of the KidneyRecurrent Renal Cell CarcinomaStage III Renal Cell Cancer+1 more
Roswell Park Cancer Institute 16
Early research (Phase 1)Looking for participantsNCT07021898
What this trial is testing

ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

Who this might be right for
Metastatic Solid Tumors
Erasca, Inc. 200
Not applicableUnknownNCT06412718
What this trial is testing

Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies

Who this might be right for
Rare DiseasesAniridiaNeurotrophic Keratopathy+5 more
IRCCS Ospedale San Raffaele 274
Not applicableStudy completedNCT05412459
What this trial is testing

99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy

Who this might be right for
HER2-positive Breast CancerFemale
Tomsk National Research Medical Center of the Russian Academy of Sciences 15
Next Page